Septerna (SEPN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 26, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and vote by June 25, 2026.
Voting matters and shareholder proposals
Election of two directors: Shalini Sharp, M.B.A., and Jake Simson, Ph.D.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Other business may be addressed as appropriate during the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all presented proposals and nominees.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Septerna
- Q2 2026 revenue reached $26.7M, net loss narrowed, and cash runway extends into 2029.SEPN
Q2 2026 - Advancing oral therapies for endocrine and immunological diseases via innovative GPCR targeting.SEPN
44th Annual J.P. Morgan Healthcare Conference - Directors and auditor ratified, pipeline advanced, and strong cash position maintained.SEPN
AGM 2026 - Lead GPCR-targeting drugs advance in trials, leveraging a novel discovery platform.SEPN
Bank of America Global Healthcare Conference 2026 - Revenue surged to $26.5M, net loss narrowed, and cash runway is secured into 2029.SEPN
Q1 2026 - Proxy covers director elections, auditor ratification, compensation, and governance policies.SEPN
Proxy filing - SEP-631 advances to phase II for urticaria after strong phase I data; SEP-479 nears phase I start.SEPN
TD Cowen 46th Annual Health Care Conference - Rapidly advancing oral GPCR therapies with strong pipeline and Novo Nordisk partnership.SEPN
Corporate presentation - Rapid GPCR drug discovery platform advances oral therapies with key data expected in 2025.SEPN
43rd Annual J.P. Morgan Healthcare Conference 2025